Pub Date : 2026-01-14eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004871
Ariana M Chao, Adam Gilden, Thomas A Wadden
Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care.
{"title":"Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.","authors":"Ariana M Chao, Adam Gilden, Thomas A Wadden","doi":"10.1371/journal.pmed.1004871","DOIUrl":"10.1371/journal.pmed.1004871","url":null,"abstract":"<p><p>Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004871"},"PeriodicalIF":9.9,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12803457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145985279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004614
Zihan Zhao, Dexia Chen, Ruixuan Wang, Xinke Zhang, Xiaobo Wen, Xueyi Zheng, Shasha Liu, Hao Chen, Yuqian Zhang, Dan Huang, Chengyou Zheng, Mengke Ma, Dan Xie, Yan Sun, Xiaosheng He, Muyan Cai
Background: Approximately 20% of patients with stage II colorectal cancer (CRC) experience tumor relapse despite standard surgical treatment. Histopathological analysis holds promise for postsurgical risk stratification and guiding adjuvant chemotherapy (ACT) decisions. The aim of this study was to use deep learning to extract explainable tissue biomarkers from whole-slide images.
Methods and findings: In this retrospective cohort study, we developed and validated SurvFinder, an interpretable deep learning framework designed to autonomously identify tissue-based risk biomarkers from hematoxylin and eosin (H&E)-stained slides. The framework aims to support individualized risk stratification and explore associations with treatment outcomes. The present study included 6,950 H&E slides from 1,604 patients with stage II CRC across four independent cohorts in China. Patients were enrolled from 2012 to 2018 and followed for a minimum of 24 months. The primary outcome of the study was relapse-free survival (RFS). Our analyses identified tertiary lymphoid structures (TLSs) as critical prognostic features in stage II CRC. The multi-view integration of TLS characteristics by SurvFinder consistently demonstrated superior predictive and prognostic accuracy across four multicenter datasets (AUROC with 95% confidence interval [CI]: 0.827 [0.789,0.864], 0.805 [0.749,0.860], 0.805 [0.748,0.861], and 0.712 [0.621,0.804]), surpassing traditional clinical prognostic parameters (hazard ratio [HR]: 8.23, 95% CI: 5.43-12.47; p < 0.001). Using explainable AI (XAI) methods, we ensured model transparency and identified key TLS features-such as their location at the tumor periphery and their maturity state-as significant factors influencing prognosis and the efficacy of adjuvant therapy. The retrospective design without prospective validation and real-world clinical deployment is the main limitation of this study.
Conclusions: Together, these results highlight the potential utility of deep learning-based histopathological analysis for automated risk stratification in stage II CRC. In particular, our findings support the relevance of TLSs as a histological biomarker with potential implications for personalizing ACT decisions.
{"title":"Multiview deep-learning-enabled histopathology for prognostic and therapeutic stratification in stage II colorectal cancer: A retrospective multicenter study.","authors":"Zihan Zhao, Dexia Chen, Ruixuan Wang, Xinke Zhang, Xiaobo Wen, Xueyi Zheng, Shasha Liu, Hao Chen, Yuqian Zhang, Dan Huang, Chengyou Zheng, Mengke Ma, Dan Xie, Yan Sun, Xiaosheng He, Muyan Cai","doi":"10.1371/journal.pmed.1004614","DOIUrl":"10.1371/journal.pmed.1004614","url":null,"abstract":"<p><strong>Background: </strong>Approximately 20% of patients with stage II colorectal cancer (CRC) experience tumor relapse despite standard surgical treatment. Histopathological analysis holds promise for postsurgical risk stratification and guiding adjuvant chemotherapy (ACT) decisions. The aim of this study was to use deep learning to extract explainable tissue biomarkers from whole-slide images.</p><p><strong>Methods and findings: </strong>In this retrospective cohort study, we developed and validated SurvFinder, an interpretable deep learning framework designed to autonomously identify tissue-based risk biomarkers from hematoxylin and eosin (H&E)-stained slides. The framework aims to support individualized risk stratification and explore associations with treatment outcomes. The present study included 6,950 H&E slides from 1,604 patients with stage II CRC across four independent cohorts in China. Patients were enrolled from 2012 to 2018 and followed for a minimum of 24 months. The primary outcome of the study was relapse-free survival (RFS). Our analyses identified tertiary lymphoid structures (TLSs) as critical prognostic features in stage II CRC. The multi-view integration of TLS characteristics by SurvFinder consistently demonstrated superior predictive and prognostic accuracy across four multicenter datasets (AUROC with 95% confidence interval [CI]: 0.827 [0.789,0.864], 0.805 [0.749,0.860], 0.805 [0.748,0.861], and 0.712 [0.621,0.804]), surpassing traditional clinical prognostic parameters (hazard ratio [HR]: 8.23, 95% CI: 5.43-12.47; p < 0.001). Using explainable AI (XAI) methods, we ensured model transparency and identified key TLS features-such as their location at the tumor periphery and their maturity state-as significant factors influencing prognosis and the efficacy of adjuvant therapy. The retrospective design without prospective validation and real-world clinical deployment is the main limitation of this study.</p><p><strong>Conclusions: </strong>Together, these results highlight the potential utility of deep learning-based histopathological analysis for automated risk stratification in stage II CRC. In particular, our findings support the relevance of TLSs as a histological biomarker with potential implications for personalizing ACT decisions.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004614"},"PeriodicalIF":9.9,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12801286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145967368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004855
Keungmo Yang, Jaejun Lee, Jeong Won Jang, Pil Soo Sung, Ji Won Han
<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) management requires complex decision-making considering tumor burden, liver function, and patient's functional performance status. Large language models (LLMs) show promise in clinical applications, but their utility in HCC treatment recommendations remains unexplored. We evaluated the clinical relevance of LLM-generated treatment recommendations by comparing concordance with real-world physician decisions and survival outcomes.</p><p><strong>Methods and findings: </strong>We analyzed 13,614 treatment-naive HCC patients diagnosed between 2008 and 2020 in the Korean Primary Liver Cancer Registry. Treatment recommendations were generated using ChatGPT 4o, Gemini 2.0, and Claude 3.5 with standardized prompts referencing the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver guidelines. Patients were classified as "matched" when LLM recommendations corresponded to actual treatments received. Overall survival (OS) was compared between matched and mismatched groups, stratified by the Barcelona Clinic Liver Cancer (BCLC) stage. Decision tree analysis identified factors influencing treatment selection patterns. Concordance rates between LLM recommendations and physician decisions were 31.1% (ChatGPT 4o), 32.7% (Gemini 2.0), and 26.8% (Claude 3.5). In BCLC-A patients, treatment concordance with LLM recommendations was associated with significantly improved survival (ChatGPT 4o HR: 0.743, 95% CI [0.665, 0.831], P < 0.001). Conversely, in BCLC-C patients, concordance was associated with worse survival outcomes (ChatGPT 4o HR: 1.650, 95% CI [1.523, 1.787], P < 0.001; Gemini 2.0 HR: 1.586, 95% CI [1.470, 1.711], P < 0.001; Claude 3.5 HR 1.483, 95% CI [1.366, 1.610], P < 0.001). In BCLC-B, concordance showed only modest or nonsignificant associations with survival across models. Decision tree analysis revealed that physicians prioritized liver function parameters, while LLMs emphasized tumor characteristics. In early-stage HCC, physicians avoided curative treatments when hepatic reserve was limited, whereas in advanced-stage HCC, physicians preferred locoregional therapies in patients with preserved liver function despite guideline recommendations for systemic therapy. This study is limited by its retrospective design, reliance on registry data without imaging information, and focus on guideline-era treatments, warranting future prospective validation.</p><p><strong>Conclusions: </strong>Concordance between LLM-generated and physician treatment decisions was associated with improved survival in early-stage HCC, whereas this association was not observed in advanced-stage disease. While LLMs may serve as adjunctive tools for guideline-concordant decisions in straightforward scenarios, their recommendations may reflect limited contextual awareness in complex clinical situations requiring individualized care. LLM recommendations should be interp
{"title":"Evaluating the clinical utility of large language models for hepatocellular carcinoma treatment recommendations: A nationwide retrospective registry study.","authors":"Keungmo Yang, Jaejun Lee, Jeong Won Jang, Pil Soo Sung, Ji Won Han","doi":"10.1371/journal.pmed.1004855","DOIUrl":"10.1371/journal.pmed.1004855","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) management requires complex decision-making considering tumor burden, liver function, and patient's functional performance status. Large language models (LLMs) show promise in clinical applications, but their utility in HCC treatment recommendations remains unexplored. We evaluated the clinical relevance of LLM-generated treatment recommendations by comparing concordance with real-world physician decisions and survival outcomes.</p><p><strong>Methods and findings: </strong>We analyzed 13,614 treatment-naive HCC patients diagnosed between 2008 and 2020 in the Korean Primary Liver Cancer Registry. Treatment recommendations were generated using ChatGPT 4o, Gemini 2.0, and Claude 3.5 with standardized prompts referencing the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver guidelines. Patients were classified as \"matched\" when LLM recommendations corresponded to actual treatments received. Overall survival (OS) was compared between matched and mismatched groups, stratified by the Barcelona Clinic Liver Cancer (BCLC) stage. Decision tree analysis identified factors influencing treatment selection patterns. Concordance rates between LLM recommendations and physician decisions were 31.1% (ChatGPT 4o), 32.7% (Gemini 2.0), and 26.8% (Claude 3.5). In BCLC-A patients, treatment concordance with LLM recommendations was associated with significantly improved survival (ChatGPT 4o HR: 0.743, 95% CI [0.665, 0.831], P < 0.001). Conversely, in BCLC-C patients, concordance was associated with worse survival outcomes (ChatGPT 4o HR: 1.650, 95% CI [1.523, 1.787], P < 0.001; Gemini 2.0 HR: 1.586, 95% CI [1.470, 1.711], P < 0.001; Claude 3.5 HR 1.483, 95% CI [1.366, 1.610], P < 0.001). In BCLC-B, concordance showed only modest or nonsignificant associations with survival across models. Decision tree analysis revealed that physicians prioritized liver function parameters, while LLMs emphasized tumor characteristics. In early-stage HCC, physicians avoided curative treatments when hepatic reserve was limited, whereas in advanced-stage HCC, physicians preferred locoregional therapies in patients with preserved liver function despite guideline recommendations for systemic therapy. This study is limited by its retrospective design, reliance on registry data without imaging information, and focus on guideline-era treatments, warranting future prospective validation.</p><p><strong>Conclusions: </strong>Concordance between LLM-generated and physician treatment decisions was associated with improved survival in early-stage HCC, whereas this association was not observed in advanced-stage disease. While LLMs may serve as adjunctive tools for guideline-concordant decisions in straightforward scenarios, their recommendations may reflect limited contextual awareness in complex clinical situations requiring individualized care. LLM recommendations should be interp","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004855"},"PeriodicalIF":9.9,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145967370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004879
Thomas D Stanton, Shaun P Keegan, Jabir A Abdulahi, Anne V Amulele, Matthew Bates, Eva Heinz, Yogesh Hooda, Weiming Hu, Kajal Jain, Samiah Kanwar, Rindidzani Magobo, Courtney P Olwagen, John M Tembo, Tolbert Sonda, Jonathan Strysko, Caroline C Tigoi, Sameen Ahmad Amin, Kyle Bittinger, Jennifer Cornick, Ebenezer Foster-Nyarko, Wilson Gumbi, Aneeta Hotwani, Naveed Iqbal, Steven M Jones, Furqan Kabir, Waqasuddin Khan, Chileshe L Musyani, Carolyn M McGann, Varsha Mittal, Ahmed M Moustafa, Patrick Musicha, James C L Mwansa, Moreka L Ndumba, Erkison E Odih, Donwilliams O Omuoyo, Oliver Pearse, Laura T Phillips, Paul J Planet, Aniqa Abdul Rasool, Charlene M C Rodrigues, Kirsty Sands, Arif M Tanmoy, Erin Theiller, Allan M Zuza, Sulagna Basu, Grace J Chan, Kenneth C Iregbu, Jean-Baptiste Mazarati, Semaria Solomon Alemayehu, Timothy R Walsh, Rabaab Zahra, Angela Dramowski, Sombo Fwoloshi, Appiah-Korang Labi, Lola Madrid, Noah Obeng-Nkrumah, David Ojok, Boaz D Wadugu, Andrew C Whitelaw, Adhisivam Bethou, Anudita Bhargava, Atul Jindal, Ruchi N Nanavati, Priyanka S Prasad, Apurba Sastry, Joveria Q Farooqi, Najia Ghanchi, Fyezah Jehan, Erum Khan, Ramesh K Agarwal, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Shabir A Madhi, Muhammad Imran Nisar, Samir K Saha, Senjuti Saha, Mari Jeeva Sankar, Kelly L Wyres, Kathryn E Holt
Background: Klebsiella pneumoniae causes ~20% of sepsis in neonates, with ~40% crude mortality. A vaccine administered to pregnant women, protecting against ≥70% of K. pneumoniae infections, could avert ~400,000 cases and ~80,000 deaths annually, mostly in Africa and South Asia. Vaccine formulations targeting the capsular polysaccharide (K) or lipopolysaccharide (O) antigens are in development. Global K. pneumoniae populations display extensive K and O diversity, necessitating a polyvalent vaccine targeted to the serotypes associated with neonatal disease in relevant geographical regions. We investigated the prevalence of K and O types associated with neonatal sepsis in Africa and South Asia to inform maternal vaccine design.
Methods and findings: We analysed 1,930 K. pneumoniae neonate blood isolates from 13 surveillance studies across 35 sites in 13 countries. We used pathogen whole-genome sequencing to predict K and O serotypes and adjust for local transmission clusters, and Bayesian hierarchical meta-analysis to estimate K and O prevalence overall and per region, treating site as a random effect. Eighty-seven K loci were identified. KL2, KL102, KL25, KL15, and KL62 accounted for 49% of isolates. We estimate that 20 K loci, combining the eight most prevalent per region, could cover 72.9% of all infections (95% credible interval: [69.4%, 76.5%]) and ≥70% in each of Eastern, Western, and Southern Africa and South Asia. Preliminary findings from three sites suggested sufficient temporal stability of K loci to maintain 20-valent K vaccine coverage over 5-10 years, but more longitudinal data are needed to support this prediction. O types were far less diverse (n = 14 types). We estimate the top-5 (O1⍺β,2⍺, O1⍺β,2β, O2⍺, O2β, and O4) would cover 86.2% [82.6, 89.9%] of total infections (76%-92% per region), while the top-10 would cover ~99% of infections in all four regions. The main limitations of our study are the reliance on genome sequences to predict K and O serotypes (as serological typing is not available) and a lack of longitudinal data to explore stability of antigen prevalence over time.
Conclusions: Neonatal sepsis is associated with diverse K and O types, with substantial geographic and temporal variation even after adjusting for localised transmission clusters. Despite this, a single 20-valent K vaccine could theoretically cover ≥70% of infections in all target regions. Locally-targeted vaccines could achieve higher coverage with lower valency, but are less feasible. In principle, very high coverage could be achieved with lower valency O-based vaccines, however, the protective efficacy against disease of antibodies targeting the O antigen remains uncertain. Further research is needed on cross-reactivity, antigen exposure, and stability of antigens over time, to better inform vaccine development.
{"title":"Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: A meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage.","authors":"Thomas D Stanton, Shaun P Keegan, Jabir A Abdulahi, Anne V Amulele, Matthew Bates, Eva Heinz, Yogesh Hooda, Weiming Hu, Kajal Jain, Samiah Kanwar, Rindidzani Magobo, Courtney P Olwagen, John M Tembo, Tolbert Sonda, Jonathan Strysko, Caroline C Tigoi, Sameen Ahmad Amin, Kyle Bittinger, Jennifer Cornick, Ebenezer Foster-Nyarko, Wilson Gumbi, Aneeta Hotwani, Naveed Iqbal, Steven M Jones, Furqan Kabir, Waqasuddin Khan, Chileshe L Musyani, Carolyn M McGann, Varsha Mittal, Ahmed M Moustafa, Patrick Musicha, James C L Mwansa, Moreka L Ndumba, Erkison E Odih, Donwilliams O Omuoyo, Oliver Pearse, Laura T Phillips, Paul J Planet, Aniqa Abdul Rasool, Charlene M C Rodrigues, Kirsty Sands, Arif M Tanmoy, Erin Theiller, Allan M Zuza, Sulagna Basu, Grace J Chan, Kenneth C Iregbu, Jean-Baptiste Mazarati, Semaria Solomon Alemayehu, Timothy R Walsh, Rabaab Zahra, Angela Dramowski, Sombo Fwoloshi, Appiah-Korang Labi, Lola Madrid, Noah Obeng-Nkrumah, David Ojok, Boaz D Wadugu, Andrew C Whitelaw, Adhisivam Bethou, Anudita Bhargava, Atul Jindal, Ruchi N Nanavati, Priyanka S Prasad, Apurba Sastry, Joveria Q Farooqi, Najia Ghanchi, Fyezah Jehan, Erum Khan, Ramesh K Agarwal, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Shabir A Madhi, Muhammad Imran Nisar, Samir K Saha, Senjuti Saha, Mari Jeeva Sankar, Kelly L Wyres, Kathryn E Holt","doi":"10.1371/journal.pmed.1004879","DOIUrl":"10.1371/journal.pmed.1004879","url":null,"abstract":"<p><strong>Background: </strong>Klebsiella pneumoniae causes ~20% of sepsis in neonates, with ~40% crude mortality. A vaccine administered to pregnant women, protecting against ≥70% of K. pneumoniae infections, could avert ~400,000 cases and ~80,000 deaths annually, mostly in Africa and South Asia. Vaccine formulations targeting the capsular polysaccharide (K) or lipopolysaccharide (O) antigens are in development. Global K. pneumoniae populations display extensive K and O diversity, necessitating a polyvalent vaccine targeted to the serotypes associated with neonatal disease in relevant geographical regions. We investigated the prevalence of K and O types associated with neonatal sepsis in Africa and South Asia to inform maternal vaccine design.</p><p><strong>Methods and findings: </strong>We analysed 1,930 K. pneumoniae neonate blood isolates from 13 surveillance studies across 35 sites in 13 countries. We used pathogen whole-genome sequencing to predict K and O serotypes and adjust for local transmission clusters, and Bayesian hierarchical meta-analysis to estimate K and O prevalence overall and per region, treating site as a random effect. Eighty-seven K loci were identified. KL2, KL102, KL25, KL15, and KL62 accounted for 49% of isolates. We estimate that 20 K loci, combining the eight most prevalent per region, could cover 72.9% of all infections (95% credible interval: [69.4%, 76.5%]) and ≥70% in each of Eastern, Western, and Southern Africa and South Asia. Preliminary findings from three sites suggested sufficient temporal stability of K loci to maintain 20-valent K vaccine coverage over 5-10 years, but more longitudinal data are needed to support this prediction. O types were far less diverse (n = 14 types). We estimate the top-5 (O1⍺β,2⍺, O1⍺β,2β, O2⍺, O2β, and O4) would cover 86.2% [82.6, 89.9%] of total infections (76%-92% per region), while the top-10 would cover ~99% of infections in all four regions. The main limitations of our study are the reliance on genome sequences to predict K and O serotypes (as serological typing is not available) and a lack of longitudinal data to explore stability of antigen prevalence over time.</p><p><strong>Conclusions: </strong>Neonatal sepsis is associated with diverse K and O types, with substantial geographic and temporal variation even after adjusting for localised transmission clusters. Despite this, a single 20-valent K vaccine could theoretically cover ≥70% of infections in all target regions. Locally-targeted vaccines could achieve higher coverage with lower valency, but are less feasible. In principle, very high coverage could be achieved with lower valency O-based vaccines, however, the protective efficacy against disease of antibodies targeting the O antigen remains uncertain. Further research is needed on cross-reactivity, antigen exposure, and stability of antigens over time, to better inform vaccine development.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004879"},"PeriodicalIF":9.9,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12810917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004792
John Holmes, Damon Morris, Duncan Gillespie, Alan Brennan, Grace Leeming, Ryan Kai Le Chen, Luke Wilson, Colin Angus
Background: Governments in several countries have introduced a minimum unit price (MUP) for alcohol. Evaluation studies suggest this has reduced alcohol-related harm, but MUPs must increase with inflation to remain effective. This paper estimates the impact of the impact of the Scottish Government's decision to increase its MUP from £0.50 to £0.65 in September 2024 and, alternative options where the MUP changes to between £0.40 and £0.80. It examines impacts on alcohol consumption, spending, and related health outcomes, how impacts vary across the population with regard to deprivation, and how drinkers move between lighter and heavier alcohol consumption groups.
Methods and findings: Policy appraisal using the Sheffield Tobacco and Alcohol Policy Model, a dynamic microsimulation model that combines data on alcohol purchasing and consumption for 10 beverage types and 800 subgroups comprising adults in the Scottish population with price elasticities and an epidemiological model. Deprivation is measured using quintiles of the Scottish Index of Multiple Deprivation. Drinker group is categorised as moderate (<14 units/week, 1 UK unit = 8 g ethanol), hazardous (>14 to ≤35/ ≤50 units/week for women/men), and harmful (>35/50 units/week for women/men). The policy appraisal estimates that, compared to retaining Scotland's MUP at £0.50, increasing the MUP to £0.65 leads to an estimated 12.0% decrease in alcohol consumption, 2.1% decrease in alcohol spending, 3,385 fewer deaths overall, and 2,578 fewer deaths wholly attributable to alcohol over 20 years. Estimated effects are largest in the quintile of the population living in the most deprived areas. Increasing the MUP to £0.65 is also estimated to reduce the proportion of drinkers consuming at harmful levels by 29.4% and the proportion consuming at hazardous levels by 8.0%. Key limitations of the study include relying on data on alcohol consumption and spending collected before the COVID-19 pandemic, synthesising consumption and spending data from separate datasets, and assuming no supply-side responses (e.g., price changes above the MUP threshold).
Conclusions: Increasing the threshold of an established MUP can lead to additional reductions in alcohol consumption, related harm, and health inequalities. Benefits accrue particularly to the most deprived and heaviest drinkers.
{"title":"Public health impacts of increasing the minimum unit price for alcohol in Scotland: A model-based appraisal.","authors":"John Holmes, Damon Morris, Duncan Gillespie, Alan Brennan, Grace Leeming, Ryan Kai Le Chen, Luke Wilson, Colin Angus","doi":"10.1371/journal.pmed.1004792","DOIUrl":"10.1371/journal.pmed.1004792","url":null,"abstract":"<p><strong>Background: </strong>Governments in several countries have introduced a minimum unit price (MUP) for alcohol. Evaluation studies suggest this has reduced alcohol-related harm, but MUPs must increase with inflation to remain effective. This paper estimates the impact of the impact of the Scottish Government's decision to increase its MUP from £0.50 to £0.65 in September 2024 and, alternative options where the MUP changes to between £0.40 and £0.80. It examines impacts on alcohol consumption, spending, and related health outcomes, how impacts vary across the population with regard to deprivation, and how drinkers move between lighter and heavier alcohol consumption groups.</p><p><strong>Methods and findings: </strong>Policy appraisal using the Sheffield Tobacco and Alcohol Policy Model, a dynamic microsimulation model that combines data on alcohol purchasing and consumption for 10 beverage types and 800 subgroups comprising adults in the Scottish population with price elasticities and an epidemiological model. Deprivation is measured using quintiles of the Scottish Index of Multiple Deprivation. Drinker group is categorised as moderate (<14 units/week, 1 UK unit = 8 g ethanol), hazardous (>14 to ≤35/ ≤50 units/week for women/men), and harmful (>35/50 units/week for women/men). The policy appraisal estimates that, compared to retaining Scotland's MUP at £0.50, increasing the MUP to £0.65 leads to an estimated 12.0% decrease in alcohol consumption, 2.1% decrease in alcohol spending, 3,385 fewer deaths overall, and 2,578 fewer deaths wholly attributable to alcohol over 20 years. Estimated effects are largest in the quintile of the population living in the most deprived areas. Increasing the MUP to £0.65 is also estimated to reduce the proportion of drinkers consuming at harmful levels by 29.4% and the proportion consuming at hazardous levels by 8.0%. Key limitations of the study include relying on data on alcohol consumption and spending collected before the COVID-19 pandemic, synthesising consumption and spending data from separate datasets, and assuming no supply-side responses (e.g., price changes above the MUP threshold).</p><p><strong>Conclusions: </strong>Increasing the threshold of an established MUP can lead to additional reductions in alcohol consumption, related harm, and health inequalities. Benefits accrue particularly to the most deprived and heaviest drinkers.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004792"},"PeriodicalIF":9.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-07eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004862
Shinji Okabayashi, Gilaad G Kaplan
Proton pump inhibitors revolutionized acid-related disorder therapy, yet widespread overuse has raised concerns about long-term safety. A recent study in PLOS Medicine presents new evidence assessing whether links between their prolonged use and upper gastrointestinal cancer are causal.
{"title":"Context matters: Causality and global epidemiology of proton pump inhibitor safety.","authors":"Shinji Okabayashi, Gilaad G Kaplan","doi":"10.1371/journal.pmed.1004862","DOIUrl":"10.1371/journal.pmed.1004862","url":null,"abstract":"<p><p>Proton pump inhibitors revolutionized acid-related disorder therapy, yet widespread overuse has raised concerns about long-term safety. A recent study in PLOS Medicine presents new evidence assessing whether links between their prolonged use and upper gastrointestinal cancer are causal.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004862"},"PeriodicalIF":9.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-06eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004842
Ibrahim O Sawaid, Zohar Din, Efrat Golan, Eytan Ruppin, Avivit Golan-Cohen, Ilan Green, Eugene Merzon, Shlomo Vinker, Abraham O Samson, Ariel Israel
<p><strong>Background: </strong>Proton pump inhibitors (PPIs) are widely used for acid-related disorders, but observational studies have raised concerns about a possible association between long-term PPI use and upper gastrointestinal (GI) cancers. These associations may reflect confounding by indication and reverse causation. We aimed to evaluate the association between PPI use and upper GI cancer while explicitly addressing these biases.</p><p><strong>Methods and findings: </strong>We conducted a matched case-control study using electronic health records from a national health organization in Israel. Cases were 875 adults (age 63.0 ± 11.9 years, 62.5% male) with incident upper GI cancer (esophageal, gastric, or duodenal) diagnosed between 2003 and 2024; each case was matched to 10 cancer-free controls (n = 8,750). Matching was performed on age, sex, ethnic sector (general, Jewish ultra-orthodox, and Arab), socioeconomic status, and year of enrollment. PPI exposure was ascertained from pharmacy records and modeled in discrete pre-diagnosis windows (0-6 months, 6-12 months, 1-3 years, and 3-10 years). Multivariable conditional logistic regression estimated adjusted odds ratios (aORs) and confidence intervals (CIs), with covariates including age, smoking, body mass index, socioeconomic status, healthcare utilization, pregnancy history (in women), alcohol use, Helicobacter pylori diagnosis, and upper GI symptom-related diagnoses (e.g., gastroesophageal reflux, gastritis, peptic ulcer disease). In models without adjustment for symptom-related diagnoses, PPI use was associated with increased odds of cancer (e.g., esomeprazole aOR 4.01, 95% CI 3.20, 5.03, p < 0.001; omeprazole aOR 2.38, 95% CI 1.99, 2.85, p < 0.001). When exposure was modeled by time window, associations diminished for exposures >1 year before diagnosis. After excluding the final year before diagnosis and adjusting for symptom-related diagnoses, we did not detect a harmful association between PPI use and upper GI cancer. Remote use (>3 years) was instead associated with lower odds (e.g., omeprazole aOR 0.62, 95% CI 0.51, 0.75, p < 0.001), with similar patterns in a gastric-only subgroup (701 cases, 7,010 controls). Key limitations include potential residual confounding, lack of direct dietary and family-history data, and incomplete capture of over-the-counter PPI use.</p><p><strong>Conclusions: </strong>Apparent harmful associations between PPI use and upper GI cancer were concentrated in the months immediately preceding diagnosis and disappeared after adjusting for diagnostic context and excluding the final year before diagnosis. In these adjusted analyses, we found no evidence of increased odds with long-term PPI use, and remote use (>3 years before diagnosis) was associated with reduced cancer odds for omeprazole and lansoprazole. These findings underscore the importance of investigating new-onset upper GI symptoms rather than attributing malignancy risk to acid-suppressive therapy
背景:质子泵抑制剂(PPIs)广泛用于酸相关疾病,但观察性研究提出了长期使用PPI与上胃肠道(GI)癌症之间可能存在关联的担忧。这些关联可能反映了指征和反向因果关系的混淆。我们的目的是评估PPI使用与上消化道癌症之间的关系,同时明确解决这些偏差。方法和发现:我们使用来自以色列国家卫生组织的电子健康记录进行了匹配的病例对照研究。2003年至2024年间诊断为上消化道肿瘤(食管癌、胃癌或十二指肠癌)的成人875例(年龄63.0±11.9岁,男性62.5%);每个病例与10个无癌对照(n = 8,750)相匹配。根据年龄、性别、民族(普通、犹太极端正统派和阿拉伯)、社会经济地位和入学年份进行匹配。从药房记录中确定PPI暴露,并在离散的诊断前窗口(0-6个月,6-12个月,1-3年和3-10年)建立模型。多变量条件logistic回归估计校正优势比(aORs)和置信区间(CIs),协变量包括年龄、吸烟、体重指数、社会经济地位、医疗保健利用、妊娠史(女性)、酒精使用、幽门螺杆菌诊断和上消化道症状相关诊断(如胃食管反流、胃炎、消化性溃疡疾病)。在没有调整症状相关诊断的模型中,PPI的使用与癌症发病率增加相关(例如,在诊断前1年,埃索美拉唑的or为4.01,95% CI为3.20,5.03,p)。在排除诊断前的最后一年并调整症状相关诊断后,我们没有发现PPI使用与上消化道癌之间存在有害的关联。相反,远程使用(>3年)与较低的风险相关(例如,奥美拉唑aOR 0.62, 95% CI 0.51, 0.75, p)。结论:PPI使用与上消化道癌症之间的明显有害关联集中在诊断前几个月,在调整诊断背景并排除诊断前最后一年后消失。在这些调整后的分析中,我们没有发现长期使用PPI的风险增加的证据,而远程使用奥美拉唑和兰索拉唑与降低癌症风险相关(诊断前3年)。这些发现强调了研究新发上消化道症状的重要性,而不是将恶性肿瘤风险归因于抑酸治疗。
{"title":"Association between proton pump inhibitor use and upper gastrointestinal cancer: A matched case-control study accounting for reverse causation and confounding by indication.","authors":"Ibrahim O Sawaid, Zohar Din, Efrat Golan, Eytan Ruppin, Avivit Golan-Cohen, Ilan Green, Eugene Merzon, Shlomo Vinker, Abraham O Samson, Ariel Israel","doi":"10.1371/journal.pmed.1004842","DOIUrl":"10.1371/journal.pmed.1004842","url":null,"abstract":"<p><strong>Background: </strong>Proton pump inhibitors (PPIs) are widely used for acid-related disorders, but observational studies have raised concerns about a possible association between long-term PPI use and upper gastrointestinal (GI) cancers. These associations may reflect confounding by indication and reverse causation. We aimed to evaluate the association between PPI use and upper GI cancer while explicitly addressing these biases.</p><p><strong>Methods and findings: </strong>We conducted a matched case-control study using electronic health records from a national health organization in Israel. Cases were 875 adults (age 63.0 ± 11.9 years, 62.5% male) with incident upper GI cancer (esophageal, gastric, or duodenal) diagnosed between 2003 and 2024; each case was matched to 10 cancer-free controls (n = 8,750). Matching was performed on age, sex, ethnic sector (general, Jewish ultra-orthodox, and Arab), socioeconomic status, and year of enrollment. PPI exposure was ascertained from pharmacy records and modeled in discrete pre-diagnosis windows (0-6 months, 6-12 months, 1-3 years, and 3-10 years). Multivariable conditional logistic regression estimated adjusted odds ratios (aORs) and confidence intervals (CIs), with covariates including age, smoking, body mass index, socioeconomic status, healthcare utilization, pregnancy history (in women), alcohol use, Helicobacter pylori diagnosis, and upper GI symptom-related diagnoses (e.g., gastroesophageal reflux, gastritis, peptic ulcer disease). In models without adjustment for symptom-related diagnoses, PPI use was associated with increased odds of cancer (e.g., esomeprazole aOR 4.01, 95% CI 3.20, 5.03, p < 0.001; omeprazole aOR 2.38, 95% CI 1.99, 2.85, p < 0.001). When exposure was modeled by time window, associations diminished for exposures >1 year before diagnosis. After excluding the final year before diagnosis and adjusting for symptom-related diagnoses, we did not detect a harmful association between PPI use and upper GI cancer. Remote use (>3 years) was instead associated with lower odds (e.g., omeprazole aOR 0.62, 95% CI 0.51, 0.75, p < 0.001), with similar patterns in a gastric-only subgroup (701 cases, 7,010 controls). Key limitations include potential residual confounding, lack of direct dietary and family-history data, and incomplete capture of over-the-counter PPI use.</p><p><strong>Conclusions: </strong>Apparent harmful associations between PPI use and upper GI cancer were concentrated in the months immediately preceding diagnosis and disappeared after adjusting for diagnostic context and excluding the final year before diagnosis. In these adjusted analyses, we found no evidence of increased odds with long-term PPI use, and remote use (>3 years before diagnosis) was associated with reduced cancer odds for omeprazole and lansoprazole. These findings underscore the importance of investigating new-onset upper GI symptoms rather than attributing malignancy risk to acid-suppressive therapy","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004842"},"PeriodicalIF":9.9,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12773814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-06eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004867
Jasmin Wertz, Leah S Richmond-Rakerd
Mental health problems are known to run in families, but it is not clear to what extent this reflects nature or nurture. By disentangling these influences, a recent PLOS Medicine article sheds light on how mental health problems are transmitted across generations.
{"title":"The nature and nurture of mental health problems in the family.","authors":"Jasmin Wertz, Leah S Richmond-Rakerd","doi":"10.1371/journal.pmed.1004867","DOIUrl":"10.1371/journal.pmed.1004867","url":null,"abstract":"<p><p>Mental health problems are known to run in families, but it is not clear to what extent this reflects nature or nurture. By disentangling these influences, a recent PLOS Medicine article sheds light on how mental health problems are transmitted across generations.</p>","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004867"},"PeriodicalIF":9.9,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12773811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-05eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004873
Yi Yang, Nina Afshar, Zoe Aitken, Rebecca J Bergin, Peter Summers, Roger L Milne, Sue M Evans, Anne Kavanagh, George Disney
<p><strong>Background: </strong>Cancer is a major yet under-recognised contributor to the mortality gap between people with and without disability. Our study aims to quantify these inequalities to inform cancer control efforts to reduce the gap.</p><p><strong>Methods and findings: </strong>We used nationally-linked data (2011-2022) to construct a cohort of over 10 million adults in Australia aged 25-74 years. Disability was measured in 2011 Census as requiring assistance in core daily activities and cancer related deaths identified in national death registrations. We estimated age-standardised and age-specific cancer mortality rates, and absolute and relative mortality inequalities (rate differences and ratios) between people with and without disability. The study included 10,414,951 people. Of the 5,403,503 females, 185,801 (3.4%) reported disability; 183,594 of the 5,011,448 males (3.7%) reported disability. Over 93,940,222 person-years (9.2 years on average), 219,257 cancer-related deaths occurred. After age-standardisation, per 100,000 person-years, there were 314 (95% confidence intervals [CI]: 301, 328) more cancer related deaths in females and 410 (95% CI: 394, 427) more in males with disability (1.96 [95% CI: 1.92, 2.00], and 1.83 [95% CI: 1.80, 1.87] times higher, respectively) than those without disability. The largest absolute inequalities were for lung cancer in both females and males (67 [95% CI: 60, 73] and 103 [95% CI: 95, 111] more deaths per 100,000 person-years, respectively), followed by breast cancer in females (54 [95% CI: 49, 60] more deaths), prostate cancer in males (31 [95% CI: 26, 36] more deaths), and colorectal cancer in both sexes (30 more [95% CI: 25, 34] deaths in females and 44 [95% CI: 38, 49] more in males). By 5-year age group, lung cancer was the leading contributor to absolute inequalities in females and males aged 35 years and older. In females, across most age groups, breast cancer was the second largest contributor to absolute inequalities, followed by colorectal cancer. In males, colorectal cancer was the second largest contributor across most age groups, with prostate cancer contributing substantially to absolute inequalities in those aged 55 years and older. A substantial proportion of differences in cancer-related deaths between people with and without disability, across most age groups in both females and males were driven by cancers linked to smoking, obesity, and alcohol consumption. We found similar-sized relative inequalities between individuals with and without disability in mortality due to individual cancers in both sexes. The main limitation of the study was that disability status was measured at a single time point.</p><p><strong>Conclusions: </strong>People with disability had higher cancer mortality overall and in relation to specific cancers than people without disability. To close the gap, effort should prioritise interventions that work for people with disability across the cancer control
{"title":"Inequalities in cancer mortality between people with and without disability: A nationwide data linkage study of 10 million adults in Australia.","authors":"Yi Yang, Nina Afshar, Zoe Aitken, Rebecca J Bergin, Peter Summers, Roger L Milne, Sue M Evans, Anne Kavanagh, George Disney","doi":"10.1371/journal.pmed.1004873","DOIUrl":"10.1371/journal.pmed.1004873","url":null,"abstract":"<p><strong>Background: </strong>Cancer is a major yet under-recognised contributor to the mortality gap between people with and without disability. Our study aims to quantify these inequalities to inform cancer control efforts to reduce the gap.</p><p><strong>Methods and findings: </strong>We used nationally-linked data (2011-2022) to construct a cohort of over 10 million adults in Australia aged 25-74 years. Disability was measured in 2011 Census as requiring assistance in core daily activities and cancer related deaths identified in national death registrations. We estimated age-standardised and age-specific cancer mortality rates, and absolute and relative mortality inequalities (rate differences and ratios) between people with and without disability. The study included 10,414,951 people. Of the 5,403,503 females, 185,801 (3.4%) reported disability; 183,594 of the 5,011,448 males (3.7%) reported disability. Over 93,940,222 person-years (9.2 years on average), 219,257 cancer-related deaths occurred. After age-standardisation, per 100,000 person-years, there were 314 (95% confidence intervals [CI]: 301, 328) more cancer related deaths in females and 410 (95% CI: 394, 427) more in males with disability (1.96 [95% CI: 1.92, 2.00], and 1.83 [95% CI: 1.80, 1.87] times higher, respectively) than those without disability. The largest absolute inequalities were for lung cancer in both females and males (67 [95% CI: 60, 73] and 103 [95% CI: 95, 111] more deaths per 100,000 person-years, respectively), followed by breast cancer in females (54 [95% CI: 49, 60] more deaths), prostate cancer in males (31 [95% CI: 26, 36] more deaths), and colorectal cancer in both sexes (30 more [95% CI: 25, 34] deaths in females and 44 [95% CI: 38, 49] more in males). By 5-year age group, lung cancer was the leading contributor to absolute inequalities in females and males aged 35 years and older. In females, across most age groups, breast cancer was the second largest contributor to absolute inequalities, followed by colorectal cancer. In males, colorectal cancer was the second largest contributor across most age groups, with prostate cancer contributing substantially to absolute inequalities in those aged 55 years and older. A substantial proportion of differences in cancer-related deaths between people with and without disability, across most age groups in both females and males were driven by cancers linked to smoking, obesity, and alcohol consumption. We found similar-sized relative inequalities between individuals with and without disability in mortality due to individual cancers in both sexes. The main limitation of the study was that disability status was measured at a single time point.</p><p><strong>Conclusions: </strong>People with disability had higher cancer mortality overall and in relation to specific cancers than people without disability. To close the gap, effort should prioritise interventions that work for people with disability across the cancer control","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004873"},"PeriodicalIF":9.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-05eCollection Date: 2026-01-01DOI: 10.1371/journal.pmed.1004876
Kajsa Sjöholm, Per-Arne Svensson, Johanna C Andersson-Assarsson, Peter Jacobson, Sofie Ahlin, Cecilia Karlsson, Björn Carlsson, Felipe M Kristensson, Per Karlsson, Markku Peltonen, Lena M S Carlsson, Magdalena Taube
<p><strong>Background: </strong>Obesity increases cancer risk, whereas surgery-induced weight loss is associated with reduced risk. Risk-based patient stratification may be needed to better understand and maximize benefits of weight loss interventions in individuals with obesity. To this end, comprehensive data from high-quality studies with extended follow-up are imperative. This study examines the link between bariatric surgery and long-term cancer outcomes, focusing on patient subgroups defined by previously suggested predictors of treatment benefit, such as sex and baseline insulin levels.</p><p><strong>Methods and findings: </strong>This post-hoc analysis used data from the Swedish Obese Subjects (SOS) study, a prospective, controlled intervention trial, designed to investigate the long-term effects of bariatric surgery-induced weight loss (ClinicalTrials.gov, NCT01479452). The study was conducted at 25 public surgical departments and 480 primary healthcare centers across Sweden. Between Sept 1, 1987, and Jan 31, 2001, 2,007 per-protocol patients with obesity who underwent bariatric surgery (gastric bypass, n = 266; gastric banding, n = 376; vertical banded gastroplasty, n = 1,365) and 2,040 matched controls, receiving standard nonsurgical obesity-related care, were recruited. Inclusion criteria were age 37-60 years and a body mass index (BMI) ≥34 kg/m2 for men and ≥38 kg/m2 for women. The primary outcome measures were cancer events and cancer-related deaths, captured through nearly complete data sourced from national Swedish health registries. Female-specific cancers were defined as gynecologic and breast cancers. Analyses were adjusted (adj) for baseline age, sagittal diameter, alcohol consumption, smoking, and serum insulin levels. The study was closed on December 31, 2022. Median follow-up was 26.8 years (interquartile range (IQR) [22.9, 29.6]) in the surgery group and 24.9 years (IQR [18.7, 28.8]) in the control group. Bariatric surgery was associated with a lower overall cancer incidence rate in women (adjusted hazard ratio (HRadj) = 0.78; 95% confidence interval (CI) [0.67, 0.90]; p = 0.001), but not in men (sex-treatment interaction p = 0.013). The HRadj for overall cancer mortality rate in women was 0.78 (95% CI [0.61, 1.00]; p = 0.050). In women, surgery was associated with a lower incidence rate of both obesity-related cancers (HRadj = 0.70; 95% CI [0.58, 0.85]; p < 0.001) and female-specific cancers (HRadj = 0.60; 95% CI [0.47, 0.75]; p < 0.001). Importantly, subgroup analyses showed that the associations between surgery and female-specific cancer incidence, as well as female-specific cancer-related mortality, were stronger in women with high baseline insulin levels (insulin-treatment interaction p = 0.021 and 0.039, respectively). The main limitation is that cancer was not a predefined study outcome.</p><p><strong>Conclusions: </strong>Bariatric surgery is associated with a lower risk of cancer and cancer-related mortality in wo
背景:肥胖会增加癌症风险,而手术减肥则会降低风险。可能需要基于风险的患者分层来更好地理解和最大化肥胖个体减肥干预的益处。为此,来自高质量研究的全面数据和长期随访是必不可少的。这项研究考察了减肥手术与长期癌症预后之间的联系,重点关注了先前提出的治疗效果预测指标(如性别和基线胰岛素水平)所定义的患者亚组。方法和发现:这项事后分析使用了瑞典肥胖受试者(SOS)研究的数据,这是一项前瞻性、对照干预试验,旨在调查减肥手术诱导减肥的长期效果(ClinicalTrials.gov, NCT01479452)。这项研究是在瑞典25个公共外科部门和480个初级保健中心进行的。在1987年9月1日至2001年1月31日期间,研究人员招募了2007名接受减肥手术(胃分流术,266例;胃束带,376例;垂直胃束带成形术,1365例)的肥胖患者和2,040名接受标准非手术治疗的对照组。纳入标准为年龄37-60岁,男性体重指数(BMI)≥34 kg/m2,女性体重指数≥38 kg/m2。主要结局指标是癌症事件和癌症相关死亡,这些数据来自瑞典国家卫生登记处的几乎完整的数据。女性特有的癌症被定义为妇科和乳腺癌。根据基线年龄、矢状直径、饮酒、吸烟和血清胰岛素水平调整分析结果。该研究于2022年12月31日结束。手术组中位随访时间为26.8年(四分位间距IQR[22.9, 29.6]),对照组中位随访时间为24.9年(四分位间距IQR[18.7, 28.8])。减肥手术与女性较低的总体癌症发病率相关(调整风险比(HRadj) = 0.78;95%置信区间(CI) [0.67, 0.90];P = 0.001),但在男性中没有(性别-治疗相互作用P = 0.013)。女性总体癌症死亡率的HRadj为0.78 (95% CI [0.61, 1.00]; p = 0.050)。在女性中,手术与较低的肥胖相关癌症发病率相关(HRadj = 0.70; 95% CI [0.58, 0.85]; p)结论:减肥手术与肥胖女性较低的癌症风险和癌症相关死亡率相关,在基线胰岛素水平升高的女性中观察到的女性特异性癌症的相关性最强。在男性中,减肥手术与总体癌症发病率或死亡率无关。这些发现支持将基于风险的分层纳入肥胖护理中,以更好地定制癌症预防策略。
{"title":"Sex-specific associations between surgery-induced weight loss and cancer outcomes: A post hoc analysis of the prospective, controlled Swedish Obese Subjects study.","authors":"Kajsa Sjöholm, Per-Arne Svensson, Johanna C Andersson-Assarsson, Peter Jacobson, Sofie Ahlin, Cecilia Karlsson, Björn Carlsson, Felipe M Kristensson, Per Karlsson, Markku Peltonen, Lena M S Carlsson, Magdalena Taube","doi":"10.1371/journal.pmed.1004876","DOIUrl":"10.1371/journal.pmed.1004876","url":null,"abstract":"<p><strong>Background: </strong>Obesity increases cancer risk, whereas surgery-induced weight loss is associated with reduced risk. Risk-based patient stratification may be needed to better understand and maximize benefits of weight loss interventions in individuals with obesity. To this end, comprehensive data from high-quality studies with extended follow-up are imperative. This study examines the link between bariatric surgery and long-term cancer outcomes, focusing on patient subgroups defined by previously suggested predictors of treatment benefit, such as sex and baseline insulin levels.</p><p><strong>Methods and findings: </strong>This post-hoc analysis used data from the Swedish Obese Subjects (SOS) study, a prospective, controlled intervention trial, designed to investigate the long-term effects of bariatric surgery-induced weight loss (ClinicalTrials.gov, NCT01479452). The study was conducted at 25 public surgical departments and 480 primary healthcare centers across Sweden. Between Sept 1, 1987, and Jan 31, 2001, 2,007 per-protocol patients with obesity who underwent bariatric surgery (gastric bypass, n = 266; gastric banding, n = 376; vertical banded gastroplasty, n = 1,365) and 2,040 matched controls, receiving standard nonsurgical obesity-related care, were recruited. Inclusion criteria were age 37-60 years and a body mass index (BMI) ≥34 kg/m2 for men and ≥38 kg/m2 for women. The primary outcome measures were cancer events and cancer-related deaths, captured through nearly complete data sourced from national Swedish health registries. Female-specific cancers were defined as gynecologic and breast cancers. Analyses were adjusted (adj) for baseline age, sagittal diameter, alcohol consumption, smoking, and serum insulin levels. The study was closed on December 31, 2022. Median follow-up was 26.8 years (interquartile range (IQR) [22.9, 29.6]) in the surgery group and 24.9 years (IQR [18.7, 28.8]) in the control group. Bariatric surgery was associated with a lower overall cancer incidence rate in women (adjusted hazard ratio (HRadj) = 0.78; 95% confidence interval (CI) [0.67, 0.90]; p = 0.001), but not in men (sex-treatment interaction p = 0.013). The HRadj for overall cancer mortality rate in women was 0.78 (95% CI [0.61, 1.00]; p = 0.050). In women, surgery was associated with a lower incidence rate of both obesity-related cancers (HRadj = 0.70; 95% CI [0.58, 0.85]; p < 0.001) and female-specific cancers (HRadj = 0.60; 95% CI [0.47, 0.75]; p < 0.001). Importantly, subgroup analyses showed that the associations between surgery and female-specific cancer incidence, as well as female-specific cancer-related mortality, were stronger in women with high baseline insulin levels (insulin-treatment interaction p = 0.021 and 0.039, respectively). The main limitation is that cancer was not a predefined study outcome.</p><p><strong>Conclusions: </strong>Bariatric surgery is associated with a lower risk of cancer and cancer-related mortality in wo","PeriodicalId":49008,"journal":{"name":"PLoS Medicine","volume":"23 1","pages":"e1004876"},"PeriodicalIF":9.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}